Results 91 to 100 of about 104,861 (298)

The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments – parallels with other neurodegenerative disorders

Frontiers in Pharmacology
Poly (ADP-ribose) polymerase (PARP) enzymes are critical in repairing DNA damage induced by chemotherapy and/or radiation. Due to PARP’s role in DNA repair, inhibiting PARP leads to genomic instability and accumulation of damaged cells in cell cycle ...
Dahlia A. Ordaz, Kalpna Gupta, Daniela A. Bota, Daniela A. Bota, Daniela A. Bota, Daniela A. Bota   +5 more
doaj   +1 more source

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy

Frontiers in Pharmacology, 2020
Poly(ADP-ribose)polymerase-1 (PARP1) is a DNA repair enzyme highly expressed in the nuclei of mammalian cells, with a structure and function that have attracted interest since its discovery.
Stephen A. Jannetti, Stephen A. Jannetti, Stephen A. Jannetti, Brian M. Zeglis, Brian M. Zeglis, Brian M. Zeglis, Brian M. Zeglis, Michael R. Zalutsky, Thomas Reiner, Thomas Reiner, Thomas Reiner   +10 more
doaj   +1 more source

DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling‐Mediated Anti‐tumor Immunity

Advanced Science, EarlyView.
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang, Xi Dai, Shuaihu Li, Yingxue Chen, Yaxin Yu, Lin Wang, Kun Liu, Shuhan Lyu, Chongyang Li, Yihua Sun, Fei Li   +10 more
wiley   +1 more source

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Crown, John, Eustace, Alexander J., Mahgoub, Thamir, O'Donovan, Norma, Tryfonopoulos, Dimitrios   +4 more
core  

Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. [PDF]

, 2017
SHH Medulloblastoma (SHH-MB) is a pediatric brain tumor characterized by an inappropriate activation of the developmental Hedgehog (Hh) signaling. SHH-MB patients treated with the FDA-approved vismodegib, an Hh inhibitor that targets the transmembrane ...
Bufalieri, Francesca, Canettieri, Gianluca, Capalbo, Carlo, Coni, Sonia, DE SMAELE, Enrico, Di Magno, L, DI MARCOTULLIO, Lucia, Ferretti, Elisabetta, Kusio Kobialka, M, Mai, Antonello, Mancuso, ANNA BARBARA, Manni, Simona, Niewiadomski, P, Petroni, Marialaura, Rotili, Dante, Screpanti, Isabella, Sdruscia, Giulia, Serrao, SILVIA MARIA, Spiombi, Eleonora   +18 more
core   +2 more sources

Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer

Cell Death and Disease
PARP inhibitors and HDAC inhibitors have been approved for the clinical treatment of malignancies, but acquired resistance of or limited effects on solid tumors with a single agent remain as challenges.
Qingyun Zhu, Qiuzi Dai, Lei Zhao, Chang Zheng, Qinyuan Li, Zigao Yuan, Lulu Li, Zhuoye Xie, Zixuan Qiu, Wenjun Huang, Guowen Liu, Xuyu Zu, Bizhu Chu, Yuyang Jiang   +13 more
doaj   +1 more source

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes

Haematologica, 2009
Background Aberrant or impaired repair of double-strand DNA breaks is a common feature of de novo acute myeloid leukemia and myelodysplastic syndromes.
Terry J. Gaymes, Sydney Shall, Lee J. MacPherson, Natalie A. Twine, Nicholas C. Lea, Farzin Farzaneh, Ghulam J. Mufti   +6 more
doaj   +1 more source

Delivery of Pleckstrin‐Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis

Advanced Science, EarlyView.
Current therapies curb tumor growth but not metastasis. Obscurin, a giant metastasis suppressor lost in breast cancer, restrains PI3K/Akt signaling but is impractical to restore. We deploy a mini‐obscurin, comprising the obscurin‐PH‐domain, which sequesters PI3K‐p85, potently suppressing invasion and metastasis.
Matthew Eason, Anindya Sen, Suhan Cho, Se Jong Lee, Keyata Thompson, Md Musavvir Mahmud, Poornima Dubey, Talia Guardia, Anthony Kim, Stuart Martin, Nathan Wright, Konstantinos Konstantopoulos, Aikaterini Kontrogianni‐Konstantopoulos   +12 more
wiley   +1 more source

Update on Combination Strategies of PARP Inhibitors

Cancer Control
The application of PARP inhibitors has revolutionized cancer treatment and has achieved significant advancements, particularly with regard to tumors with defects in genes involved in homologous recombination repair (HRR) processes, such as BRCA1 and ...
Zhuoqun Lin, Lingfang Wang PhD, Ziyu Xing, Fenfen Wang MD, Xiaodong Cheng MD   +4 more
doaj   +1 more source

SMAD4 Palmitoylation Drives a Metabolic‐Transcriptional Circuit to Promote Tumorigenesis and Confers Radiosensitivity in Pancreatic Cancer

Advanced Science, EarlyView.
This study identifies palmitoylation as a novel regulatory modification of SMAD4, mediated by ZDHHC22/APT2. It activates fatty acid synthesis, creating a self‐reinforcing SMAD4–FASN–palmitate feedback loop that drives pancreatic cancer growth and enhances radiotherapy sensitivity.
Yang Wang, Shan Zhang, Junping Bai, Xiaobing Li, Yi Han, Min Ji, Chongyi Jiang, Xiaobei Ge, Tianyu Yu, Yongying Hou, Jun Zhang, Wangting Li, Yiran Song, Jiaying Cai, Yingqun Zhou, Liwei An, Feng Wang   +16 more
wiley   +1 more source